Genistein

Genistein

SCHEMBL554356

O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12.O=c1c(-c2ccccc2)coc2ccccc12

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.79
MAPT P10636 7/20 0.79
ALDH1A1 P00352 7/20 0.79
HPGD P15428 7/20 0.79
TP53 P04637 6/20 0.79
MEN1 O00255 5/20 0.79
KMT2A Q03164 5/20 0.79
ALOX15 P16050 5/20 0.79
HSD17B10 Q99714 5/20 0.79
CYP3A4 P08684 4/20 0.79
ALOX12 P18054 4/20 0.79
BLM P54132 3/20 0.79
USP2 O75604 1/20 0.79
BRCA1 P38398 1/20 0.79
RAB9A P51151 8/20 0.76
NPC1 O15118 7/20 0.76
POLB P06746 4/20 0.76
HSD17B2 P37059 3/20 0.76
AKR1B10 O60218 3/20 0.76
LMNA P02545 3/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Genistein SCHEMBL7563328 0.90 SMN1; SMN2 (0.89) SMN1; SMN2MAPTALDH1A1HPGDTP53
SCHEMBL10623004 0.89 SMN1; SMN2 (0.94) SMN1; SMN2MAPTALDH1A1HPGDTP53
5,7-Dihydroxyisoflavone SCHEMBL1586459 0.89 MEN1 (1.00) SMN1; SMN2MAPTALDH1A1HPGDTP53
Genistein SCHEMBL5801778 0.88 SMN1; SMN2 (0.84) SMN1; SMN2MAPTALDH1A1HPGDTP53
Genistein SCHEMBL554056 0.87 MAPT (1.00) SMN1; SMN2MAPTALDH1A1HPGDTP53
Genistein SCHEMBL19166 0.87 MAPT (1.00) SMN1; SMN2MAPTALDH1A1HPGDTP53
Genistein SCHEMBL29352944 0.87 MAPT (1.00) SMN1; SMN2MAPTALDH1A1HPGDTP53
Daidzein SCHEMBL2025991 0.86 KDM4E (0.86) SMN1; SMN2MAPTALDH1A1HPGDTP53
Genistein SCHEMBL830735 0.86 SMN1; SMN2 (0.67) SMN1; SMN2MAPTALDH1A1HPGDTP53
Genistein SCHEMBL551801 0.86 MAPT (0.97) SMN1; SMN2MAPTALDH1A1HPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 486 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116987747-A Preparation method and application of extracellular polysaccharide based on monascus induced by genistein 南昌大学 2023-11-03 CN claimed
WO-2020161522-A1 FIBER-BASED COMPOSITION THD S.P.A. (IT) 2020-08-13 WO claimed
US-10610563-B2 Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2 BIOXCEL CORPORATION (US) 2020-04-07 US claimed
EP-2603222-B1 COMBINATORY CANCER TREATMENT UNIV MONTREAL (CA) 2018-10-17 EP claimed
US-20170360872-A1 USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 BIOXCEL CORPORATION (US) 2017-12-21 US claimed
EP-2709629-B1 NOVEL CANCER THERAPIES AND METHODS NUBER ULRIKE (SE) 2017-10-11 EP claimed
EP-3224263-A1 USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 Bioxcel Corporation (US) 2017-10-04 EP claimed
US-9429574-B2 Cancer therapies and methods NUBER ULRIKE (SE) 2016-08-30 US claimed
CN-105777692-A Method for extracting and determining soybean isoflavones 河南省农业科学院芝麻研究中心 2016-07-20 CN claimed
WO-2016085943-A1 USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 RASTELLI, LUCA (US) 2016-06-02 WO claimed
EP-2603222-A1 COMBINATORY CANCER TREATMENT UNIVERSITE DE MONTREAL (CA) 2013-06-19 EP claimed
WO-2012164234-A1 NOVEL TREATMENTS MD PHARMA AB (SE) 2012-12-06 WO claimed
WO-2012156463-A1 NOVEL CANCER THERAPIES AND METHODS NUBER ULRIKE (SE) 2012-11-22 WO claimed
WO-2012019284-A1 COMBINATORY CANCER TREATMENT UNIVERSITE DE MONTREAL (CA) 2012-02-16 WO claimed
CN-101795699-A Fructus Lycii and inflammation NESTEC SA 2010-08-04 CN claimed
EP-1143988-B1 COMPOSITION COMPRISING SOY PROTEIN, DIETARY FIBRES AND A PHYTOESTROGEN COMPOUND AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF TYPE 2 DIABETES, THE METABOLIC SYNDROME AND ASSOCIATED CARDIOVASCULAR DISEASES NUTRI PHARMA AS (NO) 2004-02-18 EP claimed
EP-1133308-B1 COMPOSITION COMPRISING SOY PROTEIN, DIETARY FIBRES AND A PHYTOESTROGEN COMPOUND AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF CARDIOVASCULAR DISEASES NUTRI PHARMA AS (NO) 2003-11-12 EP claimed
US-6596289-B1 Knitted garment of cotton, nylon or polyester adapted for tight fitting; contains polyimine which partially decomposes from exposure to skin pH, moisture and/or heat releasing ascorbic acid, lipoic acid and/or isoflavones PUGLIESE PETER T (US) 2003-07-22 US claimed
EP-1133307-B1 USE OF A COMPOSITION COMPRISING SOY PROTEIN, DIETARY FIBRES AND A PHYTOESTROGEN COMPOUND IN THE PREVENTION AND/OR TREATMENT OF PULMONARY DISEASES NUTRI PHARMA AS (NO) 2003-06-11 EP claimed
EP-1038531-A2 A composition comprising soybean isoflavones and a method for the production thereof Ajinomoto Co., Inc. (JP) 2000-09-27 EP claimed